The sellside’s mid-term forecast: sunny with few hints of rain
Climbing consensus sales forecasts for 2022 suggest that last year equity analysts brushed off concerns about pricing restraints.
Led by Tandem, small-cap medtechs pump up the value in 2018
The fastest share price growth in medtech is always recorded by small-caps, but Tandem reached a new extreme last year.
Big biopharma back in favour in the third quarter
Several large-cap drug stocks registered healthy gains across the third quarter of 2018, signalling investors' growing confidence in biopharma after a disappointing…
